PBK和基质金属蛋白酶9在宫颈癌中的表达及对同步放化疗疗效的影响  

Expressions of PBK and MMP-9 and their effect on concurrent chemoradiotherapy in cervical cancer

作　　者：孙晓革 宝莹娜[2] 邱惠[1] 石静[2] 张薇 郁志龙[2] 谢丛华[1] Sun Xiaoge;Bao Yingna;Qiu Hui;Shi Jing;Zhang Wei;Yu Zhilong;Xie Conghua(Department of Radiotherapy,Zhongnan Hospital of Wuhan University,Wuhan 430071,China（Sun XG,Qiu H,Xie CH;Department of Radiotherapy,Affiliated Hospital of Inner Mongolia Medical University,Hohhot 010050,China（Bao YN,Shi J,Zhanz W,Yu ZL)

机构地区：[1]武汉大学中南医院放疗科,430071 [2]内蒙古医科大学附属医院放疗科,呼和浩特010050

出　　处：《中华放射医学与防护杂志》2018年第7期529-534,共6页Chinese Journal of Radiological Medicine and Protection

基　　金：内蒙古自治区自然科学基金项目（2016MS0856）

摘　　要：目的 探讨DNA损伤修复因子PBK（PDZ连接激酶）和基质金属蛋白酶9（MMP-9）在宫颈癌中的表达及对同步放化疗疗效的影响。方法 收集2014年1月至2016年7月共65例宫颈鳞癌根治性同步放化疗患者的病理标本，通过免疫组织化学法检测PBK和MMP-9的表达情况。体外照射采用调强放射治疗，剂量为50 Gy/25次；外照射18次后予以高剂量率后装治疗，30-36 Gy/5-6次，3-4周。外照射开始后给予每周化疗，采用单药顺铂方案，顺铂（DDP）40 mg/m2静脉滴注，连续2-6周。定期随访所有患者，分析患者临床特征、预后与PBK和MMP-9之间的关系。结果 PBK在宫颈癌标本中的阳性表达率为92.3%，MMP-9为69.2%。PBK高表达组的宫颈癌患者总生存率（OS）和疾病无进展生存率（PFS）均明显低于PBK表达低的患者（χ^2=4.324、8.068，P〈0.05），MMP-9高表达组患者的PFS明显低于低表达组（χ^2=5.134，P〈0.05），PBK和MMP-9联合高表达组的OS和PFS比联合低表达组低（χ^2=5.382、9.364，P〈0.05）。结论 PBK和MMP-9在宫颈癌组织中的表达存在差异与宫颈癌的预后相关，联合检测PBK和MMP-9的表达水平可能有助于预测宫颈癌同步放化疗后的疗效。Objective To investigate the expression of DNA damage repair factor PDZ binding kinase （PBK） and matrix metalloproteinase 9 （MMP-9） in cervical cancer and the effect on clinical outcomes of concurrent chemoradiotherapy. Methods A total of 65 cervical cancer pathological specimens were collected from January 2014 to July 2016. Immunohistochemistry was used to detect PBK and MMP-9 expression in the specimens.External irrsdeation was treated with intensity-modulated radiation therapy at a dose of 50 Gy/25 F. After 18 times of external irradiation, high-dose rate postoperative treatment was giver at a dose of 30-36 Gy/5-6 F which lasts 3-4 weeks. Weekly chemotherapy with Cisplatin（DDP） begins simultaneously at the beginning of external irradiation. DDP was administered intravenously at a dosage of 40 mg/m2 for 2 to 6 week. All patients were followed-up as routine. The relationship between clinical characteristics and prognosis of patients and the expression of PBK and MMP-9 were analyzed. Results PBK was expressed in 92.3% of tissues and MMP-9 was expressed in 69.2% of tissues. The expression of PBK was positively associated with overall survival （OS） and disease progression-free survival （PFS） of cervical cancer patients （χ^2=4.324, 8.068,P〈0.05）. The expression of MMP-9 was related with PFS （χ^2=5.134,P〈0.05）. Patients with PBK and MMP-9 expression suffered poor OS and PFS （χ^2=5.382, 9.364,P〈0.05）. Conclusions PBK and MMP-9 could be a biomarker to predict the prognosis of cervical cancer.

关 键 词：PBK(PDZ连接激酶) 基质金属蛋白酶9 同步放化疗 宫颈癌 

分 类 号：R730.55[医药卫生—肿瘤] R737.33[医药卫生—临床医学]